Loading
Total declarations
Companies
▲ Purchases (37 ops.)
▼ Sales (29 ops.)
Latest filing published 16 Jul 2026 for Cardiff Oncology, Inc., €878k.
Filing timeline
BuySaleGary W. Pace
Insider track record
Disclosed buys
37
Disclosed sells
29
T+90 hit rate
0%
T+90 mean return
-35.0%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Gary W. Pace: trading record in brief
Gary W. Pace (board member) discloses dealings in 5 companies, chiefly ResMed Inc, Pacira BioSciences, Inc. and Cardiff Oncology, Inc. Over a trading history stretching from 7 March 2006 to 14 July 2026, the count stands at 108 filings.
Market trades split into 37 purchases (€4.3M) and 29 sales (€27.0M). Netting one side against the other leaves €22.7M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 12 share grants and 26 option exercises. So far in 2026, the count stands at 2 purchases and no sales.
A typical purchase (the median) is worth €21k. Clusters matter here: 7 out of 21 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
The newest entry dates from 16 July 2026: an open-market purchase of €878k, in Cardiff Oncology, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Gary W. Pace
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
687,285 shares@ US$1.4551.65% mcap31.1% of flowCommon StockSEC:0001193125-26-306083:0
Canonical exit: 12 Oct 2026 (T+90)
30,000 sharesCommon StockSEC:0001184778-26-000009:0
Canonical exit: 16 Sept 2026 (T+90)
275,000 shares@ US$2.4530.4% of flowCommon StockSEC:0000950170-25-100882:0
Canonical exit: 28 Oct 2025 (T+90)
350,115 shares@ US$2.6056.7% of flowCommon StockSEC:0000950170-24-135767:0
Canonical exit: 11 Mar 2025 (T+90)
1,066 shares@ US$29.677.6% of flowCommon StockSEC:0001396814-24-000037:0
30,000 shares@ US$1.372.5% of flowCommon StockSEC:0001628280-23-042045:0
Canonical exit: 18 Mar 2024 (T+90)
22,950 shares@ US$0.981.4% of flowCommon StockSEC:0001628280-23-038955:0
Canonical exit: 8 Feb 2024 (T+90)
1,775 shares0Common StockSEC:0001209191-23-038025:0
7,000 shares@ US$29.9049.7% of flowCommon StockSEC:0001209191-23-029616:0
150,000 shares@ US$1.7116.8% of flowCommon StockSEC:0001628280-22-025100:0
Canonical exit: 14 Dec 2022 (T+90)
1,160 shares0Common StockSEC:0001209191-22-035227:0
7,000 shares@ US$10.8117.7% of flowCommon StockSEC:0001209191-22-016876:0
9,807 shares@ US$11.0225.1% of flowCommon StockSEC:0001209191-22-014267:0
30,000 shares@ US$6.756.1% of flowCommon StockSEC:0001628280-21-019057:0
Canonical exit: 20 Dec 2021 (T+90)
1,485 shares0Common StockSEC:0001209191-21-040097:0
15 of 15 declarations
